Inventaire


Site en français

Laboratory of Oncology and Experimental Surgery (L.O.C.E.)

Faculty of Medicine | Bordet Institute

Interfaculty institutes | U-CRC: ULB Cancer Research Center

(Code: ULB305)


MAPK pathway as a target for therapy in melanoma.

Télévie - Entreprises privées.

The project investigates new machanisms to overcome MAPK pathway inhibitors in BRAF or NRAS mutated melanomas.

TYRP1 (tyrosinase-related protein 1) as prognosis marker and target for therapy - TYRP1 function and regulation by miRNA

Région wallonne - Organisations internationales - Entreprises privées.

The gene expression level of Tyrp1 in melanoma metadteses correlates with patients' survival. The evaluation of this gene and its corresponding protein ...

Evaluation and mechanism of action of novel anticancer targeted drugs: Dasatinib, a tyrosine kinase inhibitor in melanoma.

Organisations internationales - Autres ressources extérieures.

Evaluation of the cytotoxic effect and molecular mechanisms associated with the sensitivity to the tyrosine kinase inhibitor dasatinib in a panel of me ...

Kinome, gene expression and mutation profiling to predict response to new therapies in metastatic melanoma and to bring new insights in mechanism of resistance

Autres fonds publics belges - Entreprises privées.

Kinase profiling in melanoma metatstatic tissue allows to obtain a precise image of the global activity of signaling pathways and to correlate it with  ...

Establishment and characterisation of human melanoma cell lines

Autres fonds publics belges - Entreprises privées.

It is evident that cell culture is an essential research tool. However, it is important that it represents the tissue of origine at best as well as the ...

Kinome and mutation profiling in melanoma

Télévie - Entreprises étrangères - Autres ressources extérieures.

The development of a complementary kinome/mutation screening tool that will aid in the investigation of possible treatments for patients with melanoma.